Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Other 1Gynecologic 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

Fulvestrant 64Paclitaxel 55Letrozole 54Trastuzumab 43pembrolizumab 41ribociclib 39Capecitabine 36palbociclib 35Specimen Handling 34Carboplatin 34Anastrozole 34exemestane 31abemaciclib 31Tamoxifen 31pertuzumab 29Cyclophosphamide 27Magnetic Resonance Spectroscopy 25trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 21Blood Specimen Collection 21olaparib 18Standard of Care 17Docetaxel 17Biopsy 17130-nm albumin-bound paclitaxel 16eribulin 14Taxes 14Methods 14Mastectomy, Segmental 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × Bupropion × 90 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡